NEJM posts describe phase 3 evidence that iptacopan, a complement factor B inhibitor, significantly slowed kidney-function decline in IgA nephropathy, reinforcing complement pathway targeting as a therapeutic strategy.
Alternative complement pathway overactivation contributes to IgA nephropathy.
iptacopan, a complement factor B inhibitor, significantly slowed kidney-function decline in patients with IgA nephropathy.
Original Article: Iptacopan in IgA Nephropathy — Final 24-Month Data (phase 3 APPLAUSE-IgAN trial)
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare